CorMedix Inc. · NASDAQ:CRMD

CorMedix — Merger or Acquisition (November 2026)

7 slides from CorMedix's merger presentation, Nov 9, 2026

  1. Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets

    Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets

    Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “c

  3. Slide 3: Transaction Overview and Timeline

    Slide 3: Transaction Overview and Timeline

    Transaction Overview and Timeline ➢ CorMedix Therapeutics (“CorMedix”) (NASDAQ: CRMD) has announced a definitive agreement to acquire substantially all assets Transaction of Heron Therapeutics (“Heron”) (NASDAQ: HRTX), including four commercial products (ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL®) w

  4. Slide 4: Combined CorMedix and Heron Assets

    Slide 4: Combined CorMedix and Heron Assets

    Combined CorMedix and Heron Assets Established commercial portfolio with Immediately accretive with potential products to the acute care and upside from pipeline and label expansion hematology/oncology supportive care opportunities ecosystems 11. Extends CorMedix’s portfolio into perioperative pain

  5. Slide 5: Highlights of Heron Commercial and Pipeline Assets

    Slide 5: Highlights of Heron Commercial and Pipeline Assets

    Highlights of Heron Commercial and Pipeline Assets Established integrated acute care and hematology/oncology supportive care portfolio of four FDA-approved commercial brands, 1 supported by a dedicated hospital and ambulatory surgery center (ASC) sales force with a broad footprint Diversified Q3 202

  6. Slide 6: Summary of Heron's Commercial Portfolio

    Slide 6: Summary of Heron's Commercial Portfolio

    Summary of Heron’s Commercial Portfolio Hematology/Oncology Care Products Acute Care Products Product Description IV NK1 receptor antagonist Extended-release 5-HT3 Ready-to-use IV NK1 receptor Dual-acting, extended-release formulated without polysorbate receptor antagonist designed antagonist offeri

  7. Slide 7: Combined Product Portfolio

    Slide 7: Combined Product Portfolio

    Combined Product Portfolio Creates a diversified portfolio with 12 commercial products and multiple near-term pipeline opportunities Ph III / Product Indication Pre-Clinical Ph I Ph II Commercial Registrational Hemodialysis Commercial Total Parenteral Nutrition (TPN) Ph III Hemodialysis (Pediatric l

Source: company website

More decks from CorMedix Inc.

All 34 CorMedix decks